Receptor tyrosine kinase inhibitors in cancer

被引:26
|
作者
Ebrahimi, Nasim [1 ]
Fardi, Elmira [2 ]
Ghaderi, Hajarossadat [3 ]
Palizdar, Sahar [4 ]
Khorram, Roya [5 ]
Vafadar, Reza [6 ]
Ghanaatian, Masoud [7 ]
Rezaei-Tazangi, Fatemeh [8 ]
Baziyar, Payam [9 ]
Ahmadi, Amirhossein [10 ]
Hamblin, Michael R. [11 ]
Aref, Amir Reza [12 ,13 ]
机构
[1] Univ Isfahan, Fac Sci & Technol, Dept Cell & Mol Biol & Microbiol, Genet Div, Esfahan, Iran
[2] Islamic Azad Univ Tehran, Med Branch, Tehran, Iran
[3] Pasteur Inst Iran, Lab Regenerat & Med Innovat, Tehran, Iran
[4] Islamic Azad Univ Tehran East Branch, Fac Basic Sci, Div Microbiol, Tehran, Iran
[5] Shiraz Univ Med Sci, Bone & Joint Dis Res Ctr, Dept Orthoped Surg, Shiraz, Iran
[6] Kerman Univ Med Sci, Dept Orthopead Surg, Kerman, Iran
[7] Univ Toulouse III Paul Sabatier, Master Bio Sante Parcours Toulouse Grad Sch Canc A, Toulouse, France
[8] Fasa Univ Med Sci, Sch Med, Dept Anat, Fasa, Iran
[9] Univ Mazandaran, Fac Basic Sci, Dept Mol & Cell Biol, Babolsar, Iran
[10] Persian Gulf Univ, Fac Nano & Bio Sci & Technol, Dept Biol Sci & Technol, Bushehr 75169, Iran
[11] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa
[12] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[13] Xsphera Biosci, Translat Med Grp, 6 Tide St, Boston, MA 02210 USA
基金
美国国家卫生研究院;
关键词
Targeted therapy; Immune therapy; RTK inhibitors; Drug resistance; Cancer therapy; RENAL-CELL CARCINOMA; GROWTH-FACTOR; LUNG-CANCER; THERAPEUTIC TARGET; DRUG-RESISTANCE; PHASE-III; HEPATOCELLULAR-CARCINOMA; ONCOGENIC ACTIVATION; ACQUIRED-RESISTANCE; MOLECULAR TARGET;
D O I
10.1007/s00018-023-04729-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
    Cui, J. Jean
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4427 - 4453
  • [42] Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
    Shuang Qin
    Anping Li
    Ming Yi
    Shengnan Yu
    Mingsheng Zhang
    Kongming Wu
    Journal of Hematology & Oncology, 12
  • [43] Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
    Qin, Shuang
    Li, Anping
    Yi, Ming
    Yu, Shengnan
    Zhang, Mingsheng
    Wu, Kongming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [44] Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy
    Miles, D.
    Chen, Y.
    Paprcka, S. L.
    Foley, C. N.
    Grange, R.
    Leleti, M. R.
    Zhao, X.
    Jin, L.
    Young, S. W.
    Walters, M. J.
    Powers, J. P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S38 - S39
  • [45] Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer
    Klempner, Samuel J.
    Myers, Andrea P.
    Mills, Gordon B.
    Westin, Shannon N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (16) : 2171 - 2182
  • [46] Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors
    Xu, H.
    Shu, Y.
    Jian, H.
    Shen, J.
    Xiang, J.
    Li, H.
    Li, B.
    Zhang, T.
    Zhang, L.
    Mao, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S562 - S563
  • [47] Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors
    Brose, Marcia S.
    Hong, David S.
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2023, 7
  • [48] The Receptor Tyrosine Kinase AXL in Cancer Progression
    Rankin, Erinn B.
    Giaccia, Amato J.
    CANCERS, 2016, 8 (11):
  • [49] The Met tyrosine kinase receptor in development and cancer
    Alessandra Gentile
    Livio Trusolino
    Paolo M. Comoglio
    Cancer and Metastasis Reviews, 2008, 27 : 85 - 94
  • [50] Mechanisms of receptor tyrosine kinase activation in cancer
    Du, Zhenfang
    Lovly, Christine M.
    MOLECULAR CANCER, 2018, 17